Ischemic Stroke Pipeline Insight Report | 50+ Companies and 50+ Drugs | DelveInsight

Ischemic Stroke Pipeline Insight Report | 50+ Companies and 50+ Drugs | DelveInsight

DelveInsight’s, “Ischemic Stroke Pipeline Insight 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Ischemic Stroke pipeline landscape. It covers the Ischemic Stroke pipeline drug profiles, including Ischemic Stroke clinical trials and nonclinical stage products. It also covers the Ischemic Stroke pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key takeaways from the Ischemic Stroke Pipeline Report

  • DelveInsight’s ischemic stroke pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Ischemic Stroke treatment.
  • The Leading ischemic stroke companies such as Athersys, Inc., Tarveda Therapeutics, Lumosa Therapeutics, NC Medial Research Inc, Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals, Nanjing Yoko Biomedical Co., Ltd., TrueBinding, Inc., GNT Pharma, Roche, DiaMedica Therapeutics Inc, aptaTargets, Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharmaceutical Co., Ltd., Genentech, Inc., NoNO Inc., Pharming Technologies B.V., Biogen, Avilex Pharma, SanBio, ZZ Biotech, Revalesio, Stemedica Cell Technologies, StemCyte, Ninnion, Algernon Pharmaceuticals, Primary Peptides, TMS, Tasly Pharmaceutical, Pharmazz and others are evaluating new drugs for ischemic stroke to improve the treatment landscape.
  • Promising ischemic stroke pipeline therapies in various stages of development include MultiStem, Elezanumab, LT3001, AP-188, 3K3A-APC, NIN-S119, RNS60, PP 007, Glenzocimab, SB-623, AVLX-144, BIIB 131, Conestat alfa, NCS-01, Nerinetide, UMC119-06, SY-007, Edaravone, TB006, Neu2000, Balovaptan, DM 199, ApTOLL, BMS-986177, NanO2, Tenecteplase, SIM1910-09, UMSC01, Prourokinase recombinant,  Sovateltide, and others.
  • The Ischemic Stroke Companies and academics that are working to assess challenges and seek opportunities that could influence Ischemic Stroke R&D. The Ischemic Stroke pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.

 

Discover the recent advances in ischemic stroke medication solutions @ Ischemic Stroke Pipeline Outlook

 

Recent Developmental Activities in the Ischemic Stroke Treatment Landscape

  • In July 2022, ACTICOR BIOTECH announced that it had received “PRIority Medicines” status from the European Medicines Agency (EMA) for its drug candidate, glenzocimab, for the treatment of patients with stroke.This status allowed Acticor Biotech to strengthen interactions and obtain early dialogues with regulatory authorities in order to confirm the clinical development plan for glenzocimab in the treatment of stroke.
  • In July 2022, NervGen Pharma announced the University of Cincinnati and Case Western Reserve University (CWRU) had published a pioneering preclinical study in the peer-reviewed scientific journal Cell Reports demonstrating that NervGen’s proprietary drug, NVG-291-R, promotes nervous system repair and significant functional recovery in a mouse model of severe ischemic stroke, even when treatment was initiated up to 7 days after onset.
  • In June 2022, Pharmazz Inc released positive topline results for its Phase III clinical trial that evaluated sovateltide as a treatment for acute ischemic stroke.The findings showed that, at 90 days, the modified Rankin Score (mRS) had a significantly greater number of individuals with an improvement of 2 points or greater on mRS, mRS with a significant median score reduction, and a significantly greater reduction of individuals with an improvement of 6 or more points on the NIHSS Level of Consciousness (1A)
  • In February 2022, Acticor Biotech reported positive data from its Phase Ib/IIa ACTIMIS clinical trial of glenzocimab analyzed as an add-on treatment to standard of care for acute ischemic stroke (AIS) patients.Findings showed that the trial met the primary endpoint, establishing the favourable safety profile of glenzocimab.
  • In February 2022, Bayer announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment for secondary prevention in patients with a non-cardioembolic ischemic stroke.
  • In May 2022, Athersys, Inc. announced that its partner, HEALIOS K.K. (Healios), had reported topline results for its Japan ischemic stroke study, TREASURE.Improvement in pre-specified measures of functional “independence” and good outcomes, were found such as mRS ≤2, Barthel Index ≥95 and Global Recovery, associated with MultiStem treatment. The primary endpoint, excellent outcome at 90 days, did not reach statistical significance in the population. No material differences in safety outcomes, including mortality and life-threatening adverse events between the treatment and placebo groups were noticed.

 

Ischemic Stroke Overview

Ischemic strokes occur when blood supply is cut off to part of the brain. This type of stroke accounts for the majority of all strokes. The blocked blood flow in an ischemic stroke may be caused by a blood clot or by atherosclerosis, a disease which causes narrowing of the arteries over time. Ischemic strokes can be caused by a blockage anywhere along the arteries feeding the brain. Immediate emergency treatment is critical to surviving a stroke with the least amount of damage to the brain and ability to function. Ischemic strokes occur when blood supply is cut off to part of the brain by a blood clot or narrowing of the arteries. Blood clots may be caused by an irregular heartbeat such as arrhythmia, problems with the heart valve, infection of the heart muscle, hardening of the arteries, blood-clotting disorders, inflammation of the blood vessels, or a heart attack. A less common cause of ischemic stroke occurs when blood pressure becomes too low (hypotension), reducing blood flow to the brain.

 

Find out more about the latest ischemic stroke drugs and companies @ Ischemic Stroke Treatment Landscape

 

Ischemic Stroke Emerging Drugs 

 

MultiStem: Athersys, Inc.

The company is developing MultiStem®, a proprietary stem cell product, for the treatment of diseases and conditions in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as other indications. Factors expressed by MultiStem have the potential to deliver a therapeutic benefit in several ways, such as reducing inflammation, protecting damaged or injured tissue, and enhancing the formation of new blood vessels in regions of ischemic injury. These cells exhibit a drug-like profile in that they act primarily through the production of multiple factors that regulate the immune system, protect damaged or injured cells, promote tissue repair and healing, and the cells are subsequently cleared from the body over time. Currently, it is in Phase III stage of clinical trial evaluation to treat Ischemic Stroke. 

 

Elezanumab: Tarveda Therapeutics

Elezanumab (ABT 555) is a fully humanised monoclonal antibody, inhibiting repulsive guidance molecule a (RGMa), being developed by AbbVie, for the treatment of spinal cord injuries and acute ischemic stroke. Currently, it is in Phase II stage of clinical trial evaluation to treat acute ischemic stroke. 

 

LT3001: Lumosa Therapeutics

LT3001, a novel molecule designed to restore occluded blood flow without causing hemorrhage, holds promise as a superior and safer therapy to expand the treatable population and improved the outcome after acute ischemic stroke. 

 

RNS60: Revalesio Corporation

RNS60, is being developed to treat chronic neurodegenerative diseases driven by mitochondrial dysfunction, such as amyotrophic lateral sclerosis (ALS), and to improve recovery from neurological trauma, such as ischemic stroke. RNS60 uniquely activates intracellular signaling pathways that have anti-inflammatory effects and promote mitochondrial biogenesis, cell survival, and differentiation. In addition to protecting neurons and oligodendrocytes in the central nervous system, RNS60 modulates the activity of immune cells to restore cellular homeostasis throughout the body – without the undesirable side effects common to so many of today’s medicines.

 

Ischemic Stroke Therapeutic Assessment

There are approx. 50+ key companies which are developing the therapies for Ischemic Stroke. The companies which have their Ischemic Stroke drug candidates in the most advanced stage, i.e. phase III include Athersys, Inc.

 

Learn more about the novel and emerging ischemic stroke pipeline therapies @ Ischemic Stroke Ongoing Clinical Trials

 

Scope of the Ischemic Stroke Pipeline Report

  • Coverage- Global
  • Ischemic Stroke CompaniesAthersys, Inc., Tarveda Therapeutics, Lumosa Therapeutics, NC Medial Research Inc, Acticor Biotech, Meridigen Biotech Co., Prolong Pharmaceuticals, Nanjing Yoko Biomedical Co., Ltd., TrueBinding, Inc., GNT Pharma, Roche, DiaMedica Therapeutics Inc, aptaTargets, Bristol-Myers Squibb, NuvOX Pharma, Simcere Pharmaceutical Co., Ltd., Genentech, Inc., NoNO Inc., Pharming Technologies B.V, Biogen, Avilex Pharma, SanBio, ZZ Biotech, Revalesio, Stemedica Cell Technologies, StemCyte, Ninnion, Algernon Pharmaceuticals, Primary Peptides, TMS, Tasly Pharmaceutical, Pharmazz, and others.
  • Ischemic Stroke Pipeline Therapies- MultiStem, Elezanumab, LT3001, AP-188, 3K3A-APC, NIN-S119, RNS60, PP 007, Glenzocimab, SB-623, AVLX-144, BIIB 131, Conestat alfa, NCS-01, Nerinetide, UMC119-06, SY-007, Edaravone, TB006, Neu2000, Balovaptan, DM 199, ApTOLL, BMS-986177, NanO2, Tenecteplase, SIM1910-09, UMSC01,Prourokinase recombinant,  Sovateltide, and others.
  • Ischemic Stroke Segmentation: Phases, Molecule Type, Mechanism of Action, Route of Administration

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Ischemic Stroke: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Ischemic Stroke – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. MultiStem: Athersys, Inc.
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Elezanumab: Tarveda Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. AVLX-144: Avilex Pharma
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. AP-188: Algernon Pharmaceutical
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Ischemic Stroke Key Companies
  21. Ischemic Stroke Key Products
  22. Ischemic Stroke- Unmet Needs
  23. Ischemic Stroke- Market Drivers and Barriers
  24. Ischemic Stroke- Future Perspectives and Conclusion
  25. Ischemic Stroke Analyst Views
  26. Ischemic Stroke Key Companies
  27. Appendix

 

Dive deep into rich insights for new drugs for ischemic stroke treatment, visit @ Ischemic Stroke Key Companies and Therapies

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Posted

in

by

Tags: